Ferumoxsil API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Ferumoxsil API 171544-35-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Ferumoxsil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Ferumoxsil
- Synonyms:
- Siloxane-coated superparamagnetic iron oxide
- Cas Number:
- 171544-35-7
- DrugBank number:
- DB09507
- Unique Ingredient Identifier:
- 6HJV9H13XS
General Description:
Ferumoxsil is a chemical compound identified by the CAS number 171544-35-7. It is known for its distinct pharmacological properties and applications.
Categories:
Ferumoxsil is categorized under the following therapeutic classes: Colloids, Complex Mixtures, Compounds used in a research, industrial, or household setting, Contrast Media, Ferrous Compounds, Iron Compounds, Macromolecular Substances, Magnetic Iron Oxide Nanoparticles, Magnetic Resonance Imaging Contrast Media, Metal Nanoparticles, Nanoparticles, Nanostructures, Organosilicon Compounds, Pharmaceutical Preparations, Polymers, Silicon Compounds, Superparamagnetic Contrast Media. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Ferumoxsil is a type of Contrast Media
Contrast media, a prominent category in the pharmaceutical API sector, plays a crucial role in medical imaging procedures. These specialized substances enhance the visibility of internal body structures during diagnostic tests such as X-rays, CT scans, and MRIs. By optimizing the contrast between different tissues or organs, contrast media enable healthcare professionals to obtain clearer and more detailed images for accurate diagnosis and treatment planning.
Contrast media can be classified into two main types: iodinated and gadolinium-based. Iodinated contrast agents are commonly used in X-ray and CT examinations, while gadolinium-based agents are employed in MRI scans. Both types are designed to interact with specific imaging technologies and provide contrasting properties to the surrounding tissues.
These pharmaceutical APIs are meticulously developed and undergo rigorous testing to ensure safety and efficacy. They are administered intravenously, orally, or via other routes, depending on the imaging technique and medical requirements. Contrast media are carefully formulated to optimize patient comfort and minimize adverse reactions.
Healthcare providers must consider various factors when selecting contrast media, including the patient's medical history, potential allergies, and the specific imaging procedure. Moreover, ongoing research and technological advancements in contrast media aim to improve image quality, reduce side effects, and enhance patient outcomes.
In summary, contrast media are an essential component of modern medical imaging. Their purpose is to enhance image visibility, aid in accurate diagnosis, and contribute to effective treatment planning. Through continuous advancements and stringent quality control, contrast media continue to play a vital role in improving medical imaging techniques and patient care.
